PAG has agreed to pay RMB3.8 billion ($532 million) for a 58% stake in a biotech unit of Zhejiang Hisun Pharmaceutical. It is being called the largest PE investment in China’s biotech space to date.
Hisun Pharmaceutical will retain a 42% stake in the company, known as Hisun BioRay Bio-pharmaceutical. Although Hisun BioRay was not formally established as a subsidiary until January this year, Hisun...
Michael Granoff, founder and CEO of Pomona Capital, discusses raising capital from Asian LPs, how GPs can be differentiated in a crowded secondaries market, and why he’s not keen on fund restructurings
Japanese mid-market buyout firm Tokio Marine Capital is spinning out from its corporate parent to form an independent investment manager known as T Capital Partners.
Centurium Capital, CITIC Capital and Hillhouse Capital are part of an investor group targeting a $4.6 billion take-private of China Biologic – just over a year after committing new equity to the US-listed company to protect it from other would-be acquirers.
Groww, an Indian financial technology provider focused on mutual fund investment services, has raised a $21.4 million Series B round led by US-based Ribbit Capital.